Trefny, Marcel P. http://orcid.org/0000-0001-6755-7899
Kaiser, Monika
Stanczak, Michal A.
Herzig, Petra
Savic, Spasenija
Wiese, Mark
Lardinois, Didier
Läubli, Heinz
Uhlenbrock, Franziska
Zippelius, Alfred
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_162575)
Universität Basel (Research Fund)
Article History
Received: 26 September 2019
Accepted: 30 March 2020
First Online: 15 April 2020
Compliance with ethical standards
:
: Heinz Läubli and Alfred Zippelius received research funding from Bristol-Myers Squibb. Alfred Zippelius received consulting/advisor fees from Bristol-Myers Squibb, Merck Sharp& Dohme, Hoffmann–La Roche, NBE Therapeutics, Secarna, ACM Pharma and Hookipa and maintains further non-commercial research agreements with Secarna, Hookipa, Roche and Beyondsprings. The authors declare that there are no other conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Ethikkommission Nordwestschweiz, Study Approval Number EK321/10) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from all individual participants included in the study for the use of their specimens in research and publication. This article does not contain any studies with animals performed by any of the authors.
: K562 cells (ATCC CCL-243) and HEK293T cells (ATCC CRL-3216) were purchased from ATCC, which provided detailed cell line authentication documentation. NA8-Mel was kindly provided by Dr. Romero (University of Lausanne) and their authenticity was confirmed by HLA-A2 positivity and cell morphology. NK92 cells (ATCC CRL-2407) were kindly provided by Dr. Bentires-Alj (University of Basel, Switzerland) and authenticity was certified by ATCC.